# Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI

> **NCT02298660** · PHASE4 · COMPLETED · sponsor: **Rick Hansen Institute** · enrollment: 55 (actual)

## Conditions studied

- Autonomic Dysreflexia

## Interventions

- **DRUG:** BOTOX

## Key facts

- **NCT ID:** NCT02298660
- **Lead sponsor:** Rick Hansen Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-10-17
- **Final completion:** 2017-12-15
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-12-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02298660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02298660, "Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02298660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*